Clinical Evaluation of Etafilcon A With Ketotifen
Condition: Visual Acuity
Intervention: etafilcon A with ketotifen; 1-Day ACUVUE
Intervention description: Etafilcon A with ketotifen; 1-Day ACUVUE
Intervention MeSH terms: Ketotifen
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 143.0
Sex: All
Minimum age: 18 Years
Maximum age: 40 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      This clinical study is a randomized, double-masked, bilateral, controlled, two-arm parallel
      group, multi-site, 1-Week, 2-visit dispensing study. Subjects between the ages of 18-40 will
      be randomized into a placebo arm or an investigational K-Lens arm.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Potential subjects must satisfy all of the following criteria to be enrolled in the
             study

               1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and
                  receive a fully executed copy of the form.

               2. Appear able and willing to adhere to the instructions set forth in this clinical
                  protocol.

               3. Between 18 and 39 (inclusive) years of age at the time of baseline visit.

               4. The subject must be a habitual lens wearer for a least 6 days/week and for a
                  minimum of 8 hours per day over the last month.

               5. The subject's contact lens correction must be in the range of -1.00 D to -6.00 D
                  (inclusive) in each eye.

               6. The subject's refractive cylinder must be 1.00 D or less in each eye.

               7. Have a spherocylindrical best corrected visual acuity of 20/30 or better in each
                  eye (Snellen Visual Acuity).

                  Exclusion Criteria:

          -  Potential subjects who meet any of the following criteria will be excluded from
             participating in the study:

               1. Currently pregnant or lactating.

               2. Any systemic disease (e.g., Sjögren's Syndrome), allergies, infectious disease
                  (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g.,
                  HIV), autoimmune disease (e.g. rheumatoid arthritis), or other diseases, by
                  self-report, which are known to interfere with contact lens wear and/or
                  participation in the study.

               3. Use of systemic medications (e.g., chronic steroid use) that are known to
                  interfere with contact lens wear.

               4. Any ocular allergies, infections or other ocular abnormalities that are known to
                  interfere with contact lens wear and/or participation in the study. This may
                  include, but not be limited to entropion, ectropion, extrusions, chalazia,
                  recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or
                  corneal distortion.

               5. Any corneal distortion resulting from previous hard or rigid gas permeable
                  contact lens wear, history of strabismus, or current monovision, multi-focal, or
                  toric contact lens correction.

               6. Any current use of rewetting drops or ocular medication.

               7. Any previous, or planned (during the course of the study) ocular surgery (e.g.,
                  radial keratotomy, PRK, LASIK, etc.).

               8. Any grade 3 or greater slit lamp findings (e.g., edema, corneal
                  neovascularization, corneal staining, tarsal abnormalities, conjunctival
                  injection) on the FDA Biomicroscopy Scale.

               9. Any previous history or signs of a contact lens-related corneal inflammatory
                  event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular
                  abnormality that would contraindicate contact lens wear.

              10. Any known hypersensitivity or allergic reaction to ketotifen.

              11. Participation in any eye drop, contact lens or lens care product clinical trial
                  within 14 days prior to study enrollment.

              12. Employee or immediate family member of an employee of clinical site (e.g.,
                  Investigator, Coordinator, Technician).